Oxford Biomedica Share Chat (OXB)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Oxford Biomedica	LSE:OXB	London	Ordinary Share	GB0006648157	ORD 1P

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	+0.00p	+0.00%	8.75p	8.51p	8.90p	-	-	-	0	06:30:30

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Pharmaceuticals & Biotechnology	27.8	-20.3	-0.6	-	270.24

Oxford Biomedica Share Discussion Threads

Showing 100126 to 100148 of 100150 messages

Chat Pages: 4006 4005 4004 4003 4002 4001 4000 3999 3998 3997 3996 3995 Older

Date	Subject	Author	Discuss
24/9/2017 11:03	I hope we will gather some momentum here. Please keep the informative comments coming.	city chappy	Read Full Thread Reply
24/9/2017 08:38	HTTPS://scienceofparkinsons.com/2017/09/07/voyager-therapeutics-phase-ib-clinical-trial-results/ This sounds really fantastic. Right? Well, Prosavin was one of the success stories in the gene therapy world. But please remember that the first Prosavin study was an open-label trial. The Prosavin product really needs to be tested in a double blind study. This is particularly important because there was very little actual difference between brain scans of dopamine processing before the study started and 6 months into the study – this may be one of the reasons why the company is seeking a more potent virus. And this is one of the reasons why the Voyager Therapeutics results were so pleasing to see this week. Not only did the study find an increase in the production of AADC in the putamen, but it also provided evidence that the gene therapy approach can actually work for Parkinson’s disease.	marcusl2	Read Full Thread Reply
23/9/2017 18:22	The result with Sheila Roy was a very special thing, and sort of vindicates your hopes for ProSavin. She is a walking ambassador for OXB, but as with all things OXB it's not straight forward. The protocol amendments mean that some patients were injected, some infused and most of these weren't at the same baseline when they started treatment. With small numbers in a dose escalation trial, changing patients and treatment methods halfway through probably wasn't the best thing to do with regard to conclusive trial results. The money for the second trial got spent on other things. ProSavin is probably our most valuable spin-out prospect as things stand today (i.e. without any unexpected results from a TroVax trial - or similar).	harry s truman	Read Full Thread Reply
23/9/2017 18:06	I have felt for some time that lentivector and Prosavin ( I have to admit that Prosavin has always been my favorite)and maybe something will come out of blue with lentivector.	antreg	Read Full Thread Reply
23/9/2017 17:47	It's still in there Antreg. When I wrote "With TroVax we await results", then I meant that there's always hope. But... CRC (TacTicc) seemed a "good" result, though the difference between the TroVax arm and the non TroVax arm wasn't night and day. It was an improvement and it seemed to do something, but the hope with the IRS biomarker pre-screened patients was that everybody would respond. They plainly didn't. Mesothelioma (SKOPOS) nobody has any idea as they've never said, but as various people have noted, it seems unlikely that they are hiding good news. If the result of that trial was outstandingly good, then we would probably know by now. Prostate (Vance) is a mixture of TroVax and PrimeBoost and might be the one that does it, but that won't read out anytime soon. Ovarian (Trioc) is another long term trial. Something might come of it. TroVax was why I came here. But I have to be realistic and when OXB rebranded themselves as "the lentivector company" then that doesn't include TroVax (to which they have publicly said they will spend no more money on) and there's probably a good reason for that.	harry s truman	Read Full Thread Reply
23/9/2017 15:32	Harry I am suprised that you have now dropped Trovax from your list of expectations.	antreg	Read Full Thread Reply
23/9/2017 14:22	Estimated Enrollment: 15 Study Start Date: December 2015 Estimated Primary Completion Date: February 2018 (Final data collection date for primary outcome measure) HTTPS://clinicaltrials.gov/ct2/show/NCT02640209 Eight of nine evaluable patients tested had no signs of CLL in their bone marrow at three months. CTL119 is a humanized CD19-directed CAR-T cell therapy being developed in collaboration with the University of Pennsylvania Novartis is committed to advancing a portfolio of next-generation CAR-T cell therapies HTTPS://www.novartis.com/news/media-releases/novartis-next-generation-car-t-cell-therapy-ctl119-combined-ibrutinib-shows-high	marcusl2	Read Full Thread Reply
23/9/2017 09:38	Yes Prosavin and CAR T 5T4 the main hopes for me. Perhaps TRiP will produce some income also? At least Novartis` CAR Ts are likely to do very well for us. Have a nice day.	marcusl2	Read Full Thread Reply
23/9/2017 09:13	Morning Marcus, I feel like we have been down this road before, but for RetinoStat there may be no market. Sanofi will have thought long and hard before taking the other 2 (ushstat / stargen) only. Doesn't mean that RetinoStat doesn't work or that EncorStat won't. Just that they don't see the business model working for them.Remember pram's point from the AGM about promising drugs getting dropped. It's just the business.ProSavin seems most likely to be partnered. With TroVax we await results.Anyway, have a good day.	harry s truman	Read Full Thread Reply
23/9/2017 08:42	It really is about time JD came up with something for the in-house drugs. Any deal would be very welcome. I can`t find any details about the recent presentations. Next one; September 27 4:35pm – 5:05pm OXB Cantor Fitzgerald Healthcare Conference New York, USA	marcusl2	Read Full Thread Reply
22/9/2017 23:33	Something we've gone on about many times in the past Marcus, but the people working in these charity funded studies do seem to work at a different pace than the commercially funded studies. Remember that SKOPOS / mesothelioma completed sometime before the TacTicc / CRC trial, but we've yet to see any kind of results with the former. With CRC they essentially gave us a half-time score followed by the full results within a quarter or so of when they said that they would report - and now we've had another bite of that cherry - but remembering there that CRC was the second of the current TroVax trials. SKOPOS is well overdue now.	harry s truman	Read Full Thread Reply
22/9/2017 19:54	Chester youngster cancer free for a year. hTTp://www.chesterstandard.co.uk/home/2017/09/22/gallery/inspirational-chester-youngster-erin-cross-cancer-free-for-a-year-95753/	ewads	Read Full Thread Reply
22/9/2017 17:46	That's a nice 1 million share purchase from this morning just posted now at 9.39p	beanol	Read Full Thread Reply
22/9/2017 16:25	Good find Marcus,does this all follow on from the Trovax trial in 2012?	northstand	Read Full Thread Reply
22/9/2017 16:01	ITV REPORT 22 September 2017 at 7:25am Breakthrough in bowel cancer treatment Scientists at Cardiff University have discovered a new way to prolong the life of people with bowel cancer. Bowel Cancer Credit: Cardiff University Researchers have completed clinical trials which involved treatment strategies to boost the power of the immune system of inpatients with end-stage bowel cancer. This early phase study, funded by Cancer Research Wales, is thought to be amongst the first immunotherapy trial in bowel cancer to show a significant improvement in survival outcomes for patients with advanced disease. 55 patients were recruited to the trial at Velindre Cancer Centre. Patients whose immune system could be boosted lived on average for 20months, compared to 10 months in those who failed to respond to the new treatments. Th study showed that patients who respond by generating immune responses to up-regulated, tumour proteins do well, and this is a fundamentally important finding. The clear benefit to patients opens the door for larger downstream immunotherapy trials which have the potential to expand future treatment options of colon cancer. – PROFESSOR ANDREW GODKIN, CONSULTANT GASTROENTEROLOGIST FROM CARDIFF UNIVERSITY, SCHOOL OF MEDICINE As bowel cancer represents the second leading cause of cancer death in Wales, this study represents a big step forward in the management of a disease that is very difficult to treat in the advanced stages. We as a charity are proud to have supported this work as we continue to seek further breakthroughs in this very exciting field of cancer treatment. – LIZ ANDREWS, CHARITY DIRECTOR OF CANCER RESEARCH WALES This early stage research is a step in the right direction for investigating new treatment options for people with advanced bowel cancer. Bowel Cancer UK would like to see further larger scale studies developed to determine how effective this approach could be in practice. This study is a testament to the exciting research which is taking place in Wales. – LOWRI GRIFFITHS, HEAD OF WALES FOR BOWEL CANCER UK Last updated Fri 22 Sep 2017	marcusl2	Read Full Thread Reply
22/9/2017 15:21	That is his monthly director's fee Master RSI. He opted to take all his fees in shares.	prambigear	Read Full Thread Reply
22/9/2017 14:16	DIRECTORS BUYING Dr Lorenzo Tallarigo -Chairman Friday 22 September 2017 acquired 29,685 shares @ 8.90p	master rsi	Read Full Thread Reply
22/9/2017 13:57	Squabbles = clashing egos. And rather good entertainment as long as you are not involved ;)	wageslave	Read Full Thread Reply
22/9/2017 12:35	City Chappy, the 'squabbles' are somewhat about what the long game will turn out to be	stocktastic	Read Full Thread Reply
22/9/2017 11:25	The move above 9 appears to have triggered some selling but it would be very gratifying to end the day 9+	sddavies1	Read Full Thread Reply
22/9/2017 09:35	The company seems to have finally turned the corner after a long haul. Surely that is the key point. I've never seen the point of daily posts and squabbles on discussion boards. Play the long game.	city chappy	Read Full Thread Reply
22/9/2017 07:57	Beanol, Yes, delayed publication and looks like buys. Yesterday's ratio of buys to sells, although I know it's a long way off reliable, was very high.	small crow	Read Full Thread Reply
21/9/2017 23:26	It looks like the late trades were posted later but occurred much earlier in the day?	beanol	Read Full Thread Reply

Chat Pages: 4006 4005 4004 4003 4002 4001 4000 3999 3998 3997 3996 3995 Older